People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Graviton BioScience Corp | — | Biotechnology | Series B | $93.3M | $213.0M | 2022 |
James D Boylan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James D Boylan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| BIHUA CHEN | 1 | 14 |
| Samuel D Waksal | 1 | 3 |
| Steven Gordon | 1 | 3 |
| Philip Barach | 1 | 3 |
| Samuel Waksal | 1 | 2 |
| Ran D Nussbaum | 1 | 1 |
| Bihua D. Chen | 1 | 1 |
| Stelios D Papadopoulos | 1 | 1 |
| Richard Giroux | 1 | 1 |
| Jeremy D Levin | 1 | 1 |
| David D MacMillan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.